- Home
- VRCA vs CGTX Comparison
VRCA vs CGTX Comparison
Compare VRCA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | CGTX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 158.8M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VRCA | CGTX |
|---|---|---|
| Price | $8.57 | $1.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | 383.9K | ★ 951.2K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,829,000.00 | N/A |
| Revenue This Year | $373.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | N/A |
| 52 Week Low | $3.28 | $0.22 |
| 52 Week High | $10.50 | $3.83 |
Technical Indicators
Market Signals| Indicator | VRCA | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.77 | 54.67 |
| Support Level | $6.26 | $1.69 |
| Resistance Level | $9.78 | $1.77 |
| Average True Range (ATR) | 1.16 | 0.13 |
| MACD | 0.31 | 0.03 |
| Stochastic Oscillator | 76.03 | 84.55 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.